George Dunbar Joins Akadeum Life Sciences' Board of Directors
ANN ARBOR, Mich. (PRWEB) September 06, 2018 -- Akadeum Life Sciences today announced it has appointed George Dunbar to its Board of Directors. Dunbar has spent his career as an executive and leader of numerous biotech companies.
He most recently served as president and CEO of ISTO Biologics, a private cell therapy and biologics company acquired by Thompson Street Capital in St. Louis, MO. Prior to ISTO, he was a Venture Partner with Arboretum Ventures, a leading life science venture capital firm.
Dunbar is joining Akadeum to work with the company on its current focused strategy of commercializing and growing its microbubble-based cell separation kits. “I’m excited to be joining Akadeum at a time when their initial products are being prepared for launch. The market has needed this type of radical simplification of next gen separation technologies,” said Dunbar.
Dunbar has served as CEO or Director for numerous public and private life science companies. In these roles, he has led several companies through their initial public offerings (IPOs) and acquisitions. He holds Electrical Engineering and MBA degrees from Auburn University.
“George has incredible expertise in the life science industry in leading in the adoption of new technologies. Having George on the team is already making a big impact on our strategy and operations,” said Akadeum’s CEO, Brandon McNaughton.
Dunbar joins existing board directors: Doug Neal, Brock Siegel, John Younger, and Brandon McNaughton. He also joins existing observers: Paul Brown, Patricia Glazier, and Charlie Moret. He will be serving in place of Bill Wood who served on the Akadeum board for over 3 years. “We are very grateful to Bill Wood for his contribution to Akadeum. His guidance, stewardship, and time on the board were critical to our success,” said McNaughton.
To learn about Akadeum and its microbubble products, visit https://www.akadeum.com/ or email info(at)akadeum.com.
About Akadeum Life Sciences, Inc.
Akadeum Life Sciences was established to create the next generation separation technology and to fundamentally change the way that isolating cells and other biological targets is approached. The company is using microbubbles to solve longstanding problems in the industry. Separation applications include research, in vitro diagnostics, and cell therapy. The company is located in Ann Arbor, MI and was founded in 2014 by Brandon McNaughton, PhD and John Younger, MD. Inquiries into Akadeum’s products or technology can be made at info(at)akadeum.com or http://www.akadeum.com/.
Thomas Jones, Akadeum Life Sciences, https://www.akadeum.com/, 734-707-1233, [email protected]
Share this article